12th Annual European Life Sciences CEO Forum: Partnering and Investing in Biotech & Pharma Industry

Location: Hilton Zurich Airport Hotel, Switzerland

Date: February 25th-26th 2019

zurich3.jpg
 
 
zurich4.jpg

Since 2008, the landscape of Chinese foreign direct investments in the European Union has changed dramatically. From $840 million invested in 2008, China’s annual FDI in Europe grew to $42 billion in 2017. According to a recent compilation by Bloomberg, total Chinese investments in Europe, including both mergers and acquisitions (M&A) and greenfield investments, amount to $318 billion, 45 percent more than Chinese investment in the U.S. between 2008 and 2017. China has taken over approximately 360 European companies.

Although last year saw a slight decline, it is fair to say that the long-term trend of China investing in European brands, technology and infrastructures will continue. China’s investments are also broadly spread geographically, although the largest European economies – the United Kingdom ($70 billion in cumulative Chinese investment), Italy ($31 billion), Germany ($20 billion), and France ($13 billion) – attract the largest share of Chinese capital.

zurich1.jpg

The main focus of Annual European Life Sciences CEO Forum was to address through the main challenges for 2019 in investment, partnering and alliance management. Significant participants contributed their insights in panels which covered the macro picture, as well as innovation in the different therapeutic sectors.

The forum featured keynote speeches by KOLs and about 60 selected corporate presentations from established (public and private) and emerging biotech companies seeking to promote investment and partnering opportunities. More than 350 delegates attended the event, and over 1500 face-to-face meetings taken place throughout 2 days.

Echo Hindle-Yang – Founder & CEO, MSQ Ventures, was invited as a special guest to deliver a sharp and in-depth speech at the Plenary Sessions: China-Europe Partnering & Investments Panel.

Plenary Sessions include:

  • China-Europe Partnering & Investment Panel

  • Early Stage Investor Roundtable

  • “Latest Trends in Fund Raising & Investment” – Private Equity & Venture Capital Panel

  • Pharma DealMakers Roundtable

  • “Prospects for 2019”- Global Biopharma Industry Review Panel 

  • Rising Stars: Start-Up Showcase